[Excitation-Contraction coupling and intracellular calcium cycling in failing hearts]

Shinichi Okuda1, Masafumi Yano

  • 1Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.

Clinical Calcium
|April 3, 2013
PubMed

Insights

Heart failure involves faulty excitation-contraction coupling due to altered calcium handling. Targeting calcium regulatory proteins offers a promising new therapeutic strategy for heart failure.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology

Context:

  • Heart failure (HF) pathogenesis involves impaired excitation-contraction coupling.
  • Neurohormonal imbalances, like sympathetic nervous system and renin-angiotensin system activation, drive HF progression.

Purpose:

  • To review the mechanisms of defective calcium (Ca2+) regulation in heart failure.
  • To explore the clinical potential of targeting Ca2+ regulatory proteins for HF treatment.

Summary:

  • Abnormalities in Ca2+ handling proteins, including reduced SR Ca2+-ATPase (SERCA2A) function and increased SR Ca2+ leak via cardiac ryanodine receptor (RyR2), contribute to contractile dysfunction in HF.
  • Dysregulated intracellular Ca2+ impacts troponin C binding, actin-myosin cross-bridging, and signaling pathways, exacerbating HF.
  • Diastolic Ca2+ leak can lead to arrhythmias and sudden cardiac death in HF patients.

Impact:

  • Understanding Ca2+ dysregulation provides insights into HF pathophysiology.
  • Targeting Ca2+ regulatory proteins represents a novel therapeutic avenue for heart failure.
  • This research may lead to new treatments to improve cardiac function and reduce mortality in HF.

Related Concept Videos

Excitation-Contraction Coupling in Skeletal Muscles01:20

Excitation-Contraction Coupling in Skeletal Muscles

Excitation-contraction coupling is a series of events that occur between generating an action potential and initiating a muscle contraction. It occurs at the triad, a structure found in skeletal muscle fibers that comprise a T-tubule and terminal cisternae of the sarcoplasmic reticulum on each side. These triads are visible in longitudinally sectioned muscle fibers. They are typically located at the A-I junction — the junction between the A and I bands of the sarcomere.
When an action potential...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Specialized Characteristics of Cardiac Muscles01:27

Specialized Characteristics of Cardiac Muscles

The primary role of cardiac muscles is to propel blood throughout the cardiovascular system. The cardiac muscle cells, or cardiomyocytes, exhibit specialized characteristics that allow them to perform this function.
Cardiac muscle cells are smaller than skeletal muscles, averaging 10–20 mm in diameter and 50–100 mm in length. However, they have large energy demands for continuous contraction and relaxation. This energy is almost exclusively derived from aerobic metabolism of energy reserves in...
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...